MYGN MYRIAD GENETICS INC

Nasdaq myriad.com


$ 7.79 $ -0.04 (-0.51 %)    

Tuesday, 14-Oct-2025 15:59:56 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 7.8
$ 7.83
$ 7.28 x 335
$ 8.11 x 200
$ 7.62 - $ 8.07
$ 3.76 - $ 25.25
963,794
na
725.75M
$ 1.66
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 02-28-2025 01-01-1970 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-04-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 03-01-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-05-2022 06-30-2022 10-Q
14 05-06-2022 03-31-2022 10-Q
15 02-25-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 11-09-2020 09-30-2020 10-Q
20 08-13-2020 06-30-2020 10-K
21 05-06-2020 03-31-2020 10-Q
22 02-07-2020 12-31-2019 10-Q
23 11-06-2019 09-30-2019 10-Q
24 08-13-2019 06-30-2019 10-K
25 05-08-2019 03-31-2019 10-Q
26 02-06-2019 12-31-2018 10-Q
27 11-07-2018 09-30-2018 10-Q
28 08-24-2018 06-30-2018 10-K
29 05-09-2018 03-31-2018 10-Q
30 02-07-2018 12-31-2017 10-Q
31 11-08-2017 09-30-2017 10-Q
32 08-09-2017 06-30-2017 10-K
33 05-03-2017 03-31-2017 10-Q
34 02-08-2017 12-31-2016 10-Q
35 11-02-2016 09-30-2016 10-Q
36 08-10-2016 06-30-2016 10-K
37 05-04-2016 03-31-2016 10-Q
38 02-03-2016 12-31-2015 10-Q
39 11-04-2015 09-30-2015 10-Q
40 08-12-2015 06-30-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Myriad Genetics (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (NASDAQ:SOP...

 myriad-genetics-publishes-meta-analysis-of-3532-mdd-patients-showing-genesight-psychotropic-test-improves-response-and-remission-rates-vs-standard-treatment

Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publ...

Core News & Articles

Assessment of feasibility for use of Parsortix derived circulating tumour cell (CTC) DNA with Myriad Genetics' existing tis...

 stock-market-today-us-futures-edge-higher-as-investors-await-earnings-from-mcdonalds-uber-and-walt-disney

US stock futures rose on Wed. after falling on Thurs. Trump threatened tariffs on imported pharma up to 250%. Bond yields down ...

 myriad-genetics-surges-3567-after-hours-following-strong-q2-earnings-beat-raised-revenue-guidance

After posting second-quarter results that beat revenue and EPS estimates and raising its 2025 guidance, Myriad Genetics jumped ...

 myriad-genetics-affirms-fy2025-adj-eps-guidance-of-002-002-vs-001-est-raises-fy2025-sales-guidance-from-80700m-82300m-to-81800m-82800m-vs-81040m-est

Myriad Genetics (NASDAQ:MYGN) affirms FY2025 Adj EPS guidance from $(0.02)-$0.02 to $(0.02)-$0.02 vs $(0.01) analyst estimate. ...

 myriad-genetics-q2-adj-eps-005-beats-001-estimate-sales-21310m-beat-20188m-estimate

Myriad Genetics (NASDAQ:MYGN) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.0...

 earnings-preview-myriad-genetics
Earnings Preview: Myriad Genetics
08/04/2025 20:08:20

 myriad-genetics-announces-monstar-screen-3-data-advancing-pan-cancer-mrd-testing

Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new mole...

 scotiabank-downgrades-myriad-genetics-to-sector-perform-lowers-price-target-to-6

Scotiabank analyst Sung Ji Nam downgrades Myriad Genetics (NASDAQ:MYGN) from Sector Outperform to Sector Perform and lowers ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION